Veeva Systems: UBS Raises PT to $310 from $285, Keeps Neutral Rating
ByAinvest
Thursday, Aug 28, 2025 10:05 am ET1min read
UBS--
Veeva Systems reported better-than-expected earnings for the second quarter, posting quarterly earnings of $1.99 per share, which exceeded the analyst consensus estimate of $1.90 per share. The company's quarterly sales totaled $789.081 million, beating the consensus estimate of $768.417 million [1]. These strong results have led several analysts to raise their price targets and maintain positive ratings on the stock.
Piper Sandler analyst Brent Bracelin maintained an Overweight rating and raised the price target from $325 to $355. Needham analyst Ryan MacDonald maintained a Buy rating and raised the price target from $300 to $355. Evercore ISI Group analyst Kirk Materne maintained an In-Line rating and raised the price target from $285 to $295. Truist Securities analyst Joe Meares maintained a Hold rating and raised the price target from $268 to $275. Stifel analyst David Grossman maintained a Buy rating and raised the price target from $295 to $320. BTIG analyst David Larsen maintained a Buy rating and raised the price target from $335 to $340. UBS analyst Karl Keirstead maintained a Neutral rating and raised the price target from $285 to $310 [1].
The company's CEO, Peter Gassner, expressed excitement about the company's performance, highlighting the transformational impact of Veeva AI and Veeva Data Cloud on the life sciences sector. Despite the positive earnings report and analyst sentiment, Veeva shares fell 5.5% to $277.31 on Thursday, following the announcement [1].
The recent earnings report and analyst ratings suggest that Veeva Systems is well-positioned to continue its growth trajectory in the life sciences software market. Investors should closely monitor the company's future financial performance and analyst ratings to make informed decisions.
References:
[1] https://www.benzinga.com/analyst-stock-ratings/price-target/25/08/47387036/veeva-systems-analysts-increase-their-forecasts-after-better-than-expected-q2-results
VEEV--
Veeva Systems: UBS Raises PT to $310 from $285, Keeps Neutral Rating
Veeva Systems Inc. (VEEV) saw a significant update in its analyst ratings following its second-quarter (Q2) 2025 earnings report. UBS Group, one of the leading financial services providers, raised its price target (PT) for Veeva Systems from $285 to $310, while maintaining a neutral rating on the stock [1]. This move comes amidst a wave of positive analyst sentiment surrounding the life sciences software provider.Veeva Systems reported better-than-expected earnings for the second quarter, posting quarterly earnings of $1.99 per share, which exceeded the analyst consensus estimate of $1.90 per share. The company's quarterly sales totaled $789.081 million, beating the consensus estimate of $768.417 million [1]. These strong results have led several analysts to raise their price targets and maintain positive ratings on the stock.
Piper Sandler analyst Brent Bracelin maintained an Overweight rating and raised the price target from $325 to $355. Needham analyst Ryan MacDonald maintained a Buy rating and raised the price target from $300 to $355. Evercore ISI Group analyst Kirk Materne maintained an In-Line rating and raised the price target from $285 to $295. Truist Securities analyst Joe Meares maintained a Hold rating and raised the price target from $268 to $275. Stifel analyst David Grossman maintained a Buy rating and raised the price target from $295 to $320. BTIG analyst David Larsen maintained a Buy rating and raised the price target from $335 to $340. UBS analyst Karl Keirstead maintained a Neutral rating and raised the price target from $285 to $310 [1].
The company's CEO, Peter Gassner, expressed excitement about the company's performance, highlighting the transformational impact of Veeva AI and Veeva Data Cloud on the life sciences sector. Despite the positive earnings report and analyst sentiment, Veeva shares fell 5.5% to $277.31 on Thursday, following the announcement [1].
The recent earnings report and analyst ratings suggest that Veeva Systems is well-positioned to continue its growth trajectory in the life sciences software market. Investors should closely monitor the company's future financial performance and analyst ratings to make informed decisions.
References:
[1] https://www.benzinga.com/analyst-stock-ratings/price-target/25/08/47387036/veeva-systems-analysts-increase-their-forecasts-after-better-than-expected-q2-results
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet